Susquehanna Fundamental Investments’s Ionis Pharmaceuticals IONS Stock Holding History

Susquehanna Fundamental Investments’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-158,609	Closed	-$4.79M	–	868
2025 Q1	$4.79M	Sell	158,609 -54,406	-26%	-$1.78M	0.07%	328
2024 Q4	$7.45M	Buy	+213,015	New	+$7.96M	0.11%	245
2024 Q2	$2.17M	Hold	45,574	–	–	0.05%	395
2024 Q1	$1.98M	Buy	+45,574	New	+$2.17M	0.09%	234
2023 Q2	–	Sell	-67,918	Closed	-$2.43M	–	767
2023 Q1	$2.43M	Sell	67,918 -25,517	-27%	-$958K	0.06%	333
2022 Q4	$3.53M	Sell	93,435 -60,201	-39%	-$2.53M	0.06%	360
2022 Q3	$6.79M	Buy	+153,636	New	+$6.47M	0.12%	243
2021 Q3	–	Sell	-88,273	Closed	-$3.52M	–	1789
2021 Q2	$3.52M	Buy	88,273 +33,469	+61%	+$1.31M	0.06%	408
2021 Q1	$2.46M	Buy	+54,804	New	+$3.06M	0.04%	571

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Susquehanna Fundamental Investments's IONS Position: Q2 2025 in Review

Susquehanna Fundamental Investments sold out of Ionis Pharmaceuticals (IONS) in Q2 2025, closing a stake of 158,609 shares — an estimated $4.79M sold.

Susquehanna Fundamental Investments first reported a position in IONS in Q1 2021 and held it in 9 quarters. The position peaked at $7.45M in Q4 2024. 363 funds tracked by Wall St. Rank hold IONS as of Q2 2025.

Susquehanna Fundamental Investments reported no remaining Ionis Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Susquehanna Fundamental Investments sold 158,609 Ionis Pharmaceuticals shares in Q2 2025, an estimated $4.79M.
Susquehanna Fundamental Investments first reported a position in Ionis Pharmaceuticals in Q1 2021 and held it in 9 quarters.
Susquehanna Fundamental Investments's Ionis Pharmaceuticals position peaked at $7.45M in Q4 2024.
363 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2025.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2025, filed 14 Aug 2025.